These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 29282880)

  • 1. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
    Huang B; Kuan PF
    Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying treatment differences in confirmatory trials under non-proportional hazards.
    Jiménez JL
    J Appl Stat; 2022; 49(2):466-484. PubMed ID: 35707213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint.
    Rulli E; Ghilotti F; Biagioli E; Porcu L; Marabese M; D'Incalci M; Bellocco R; Torri V
    Br J Cancer; 2018 Dec; 119(12):1456-1463. PubMed ID: 30420618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic RMST curves for survival analysis in clinical trials.
    Liao JJZ; Liu GF; Wu WC
    BMC Med Res Methodol; 2020 Aug; 20(1):218. PubMed ID: 32854619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Application of restricted mean survival time in clinical follow-up study].
    Yang ZJ; Lyu JJ; Hou YW; Chen Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Feb; 40(2):247-250. PubMed ID: 30744281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.
    Pak K; Uno H; Kim DH; Tian L; Kane RC; Takeuchi M; Fu H; Claggett B; Wei LJ
    JAMA Oncol; 2017 Dec; 3(12):1692-1696. PubMed ID: 28975263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.
    Trinquart L; Jacot J; Conner SC; Porcher R
    J Clin Oncol; 2016 May; 34(15):1813-9. PubMed ID: 26884584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity Analysis for Restricted Mean Survival Time When Survival Curves Have Divergent Tails.
    Ueno K; Morita S
    Ther Innov Regul Sci; 2023 May; 57(3):467-471. PubMed ID: 36596962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of Restricted Mean Survival Time Based Methods and Traditional Survival Methods: An Application in an Oncological Data.
    Huang Q; Tian C
    Comput Math Methods Med; 2022; 2022():7264382. PubMed ID: 36619796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restricted mean survival time as a summary measure of time-to-event outcome.
    Hasegawa T; Misawa S; Nakagawa S; Tanaka S; Tanase T; Ugai H; Wakana A; Yodo Y; Tsuchiya S; Suganami H;
    Pharm Stat; 2020 Jul; 19(4):436-453. PubMed ID: 32072769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer.
    Liang F; Zhang S; Wang Q; Li W
    Ann Oncol; 2018 May; 29(5):1320-1324. PubMed ID: 29788167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial.
    Abulizi X; Ribaudo HJ; Flandre P
    J Acquir Immune Defic Syndr; 2019 May; 81(1):44-51. PubMed ID: 30789450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Biology and Survival Analysis in Cancer Trials: Restricted Mean Survival Time Analysis versus Hazard Ratios.
    A'Hern RP
    Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):e75-e80. PubMed ID: 29776805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials.
    Péron J; Roy P; Ozenne B; Roche L; Buyse M
    JAMA Oncol; 2016 Jul; 2(7):901-5. PubMed ID: 27124210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring Survival Benefit in Health Technology Assessment in the Presence of Nonproportional Hazards.
    Monnickendam G; Zhu M; McKendrick J; Su Y
    Value Health; 2019 Apr; 22(4):431-438. PubMed ID: 30975394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omnibus test for restricted mean survival time based on influence function.
    Gu J; Fan Y; Yin G
    Stat Methods Med Res; 2023 Jun; 32(6):1082-1099. PubMed ID: 37015346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interpretation and Application of Restricted Mean Survival Time].
    Hasegawa T
    Gan To Kagaku Ryoho; 2022 Apr; 49(4):389-396. PubMed ID: 35444119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On assessing survival benefit of immunotherapy using long-term restricted mean survival time.
    Horiguchi M; Tian L; Uno H
    Stat Med; 2023 Apr; 42(8):1139-1155. PubMed ID: 36653933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
    Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
    JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.